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Abstract 
The pore‑forming protein epsilon toxin (Etx) from Clostridium perfringens produces acute perivascular edema affecting 
several organs, especially the brain and lungs. Despite the toxin evident effect on microvasculature and endothelial 
cells, the underlying molecular and cellular mechanisms remain obscure. Moreover, no Etx‑sensitive endothelial cell 
model has been identified to date. Here, we characterize the mouse lung endothelial cell line 1G11 as an Etx‑sensitive 
cell line and compare it with the well‑characterized Etx‑sensitive Madin‑Darby canine kidney epithelial cell line. Sev‑
eral experimental approaches, including morphological and cytotoxic assays, clearly demonstrate that the 1G11 cell 
line is highly sensitive to Etx and show the specific binding, oligomerization, and pore‑forming activity of the toxin 
in these cells. Recently, the myelin and lymphocyte (MAL) protein has been postulated as a putative receptor for Etx. 
Here, we show the presence of Mal mRNA in the 1G11 cell line and the presence of the MAL protein in the endothe‑
lium of some mouse lung vessels, supporting the hypothesis that this protein is a key element in the Etx intoxication 
pathway. The existence of an Etx‑sensitive cell line of endothelial origin would help shed light on the cellular and 
molecular mechanisms underlying Etx‑induced edema and its consequences.
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Introduction
Clostridium perfringens types B and D produce severe 
and rapidly fatal enterotoxemia in ruminants, caus-
ing a lethality rate as high as 100% and substantial eco-
nomic losses [1]. Both strains produce one of the most 
lethal clostridial toxins, the epsilon toxin (Etx). Etx is a 
protein synthesized as a very low-active molecule, the 
epsilon prototoxin (pEtx), by the bacteria present in the 
gut and becomes fully active after proteolytic cleavage 
of the C and N terminal residues [2, 3]. Once active, Etx 
alters intestinal permeability [4], enters the gut vascu-
lature, and permeabilizes vascular endothelia [5], lead-
ing to various histological changes that include brain, 
lung, and heart edema in sheep and necrotizing colitis, 
pulmonary edema, and hydropericardium in goats [6, 7]. 
Following intravenous (i.v.) administration to mice, large 
amounts of radiolabeled Etx have been found in brain 
and kidneys with small amounts in heart, lungs, liver, 
and stomach [8]. Similar results have been observed in 
mice after i.v. administration of acute doses of Etx bound 
to green fluorescent protein (GFP-Etx), with Etx mainly 
being detected in kidneys, producing the death of epithe-
lial cells from distal tubules and brain [9, 10]. It has also 
been demonstrated that Etx crosses the blood-brain bar-
rier (BBB) [11], producing permeabilization [12–16] and 
endothelial cell damage in brain microvasculature [17]. 
The recombinant protein GFP-Etx has been successfully 
used as a tool to study Etx binding and toxic effects [9, 
18]. Etx [19–21] and GFP-Etx mutants [22] have been 
tested by i.v. administration to mice. Mutants without a 
lethal effect (GFP-Etx-V56C/F118C and GFP-EtxH106P) 
did not cross the BBB [22], suggesting a direct correlation 
between the capacity of Etx to cross the BBB and lethality 
[23–26].
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In addition, the effects of i.v. injection of Etx have been 
studied in a series of other animal species [27]. These 
studies have shown that Etx is required to induce most 
of the effects of natural intoxication, producing general-
ized edema in many tissues and organs, the most signifi-
cant effects being acute pulmonary and cerebral edema 
[2, 28]. Moreover, the interstitial perivascular and alveo-
lar edema produced in lungs of sheep and goats inocu-
lated intraduodenally with Clostridium perfringens type 
D were attributable to the action of Etx [6]. Transmission 
electron microscopy has shown that the effect of Etx on 
vascular endothelia is associated with endothelial cell 
injury rather than intercellular junction disassembly [5, 
15]. Thus, Etx has been directly implicated in vascular 
endothelium damage. Moreover, Adamson and collabo-
rators perfused Etx in mesentery venular microvessels 
of rats and found increased vessel wall permeability with 
direct damage to the endothelium [5]. However, attempts 
to reproduce these effects in  vitro with endothelial cell 
cultures from aortic segments have been unsuccess-
ful [29]. There is currently no cellular model for in vitro 
studies, and previous research using endothelial cell lines 
from various animal species (including human umbilical 
endothelial cells) has not shown any effect of Etx [29], 
suggesting that only a selected set of endothelial cells are 
sensitive to Etx.
At the cellular level, most of the steps in the cytotoxic 
mechanism of Etx have been defined using the Madin–
Darby canine kidney (MDCK) epithelial cell line: a canine 
renal tubular cell model that is highly sensitive to Etx. In 
this model, the toxin forms pores in the cell plasma mem-
brane after binding and self-assembly forming oligomers 
[2, 11, 30]. Moreover, Etx shows a high structural homol-
ogy to aerolysin, a pore-forming toxin (PFT), and conse-
quently has been included in the aerolysin family of PFTs 
[31]. One of the main features of Etx is its high specific-
ity to cellular models. Besides MDCK, very few cell lines 
are sensitive to the toxin, a characteristic that depends on 
the expression of a putative receptor, or receptors, on the 
cell surface, and the most promising candidate proteins 
are located in the detergent-resistant membrane domains 
or lipid rafts. It has been shown that the myelin and 
lymphocyte (MAL) protein, a lipid raft-associated pro-
tein [32] present in myelin and lymphocytes, is essential 
for Etx activity and is thereby considered a possible cell 
membrane receptor for Etx [33]. Moreover, Etx causes 
selective death of oligodendrocytes, the mature myelin-
producing cells in the central nervous system [34], lead-
ing to demyelination [35], and this effect is dependent 
on MAL expression [34]. In addition, Etx produces cyto-
toxicity in T-lymphocytes, which also express the MAL 
protein [36]. Furthermore, the MAL protein has been 
identified in polarized epithelial cell lines, including the 
renal MDCK cell line [37, 38] and Fischer rat thyroid 
(FRT) cells [39], in which Etx is also cytotoxic [40]. The 
MAL protein has also been detected in many tissues such 
as myelin structures of the nervous system, distal and 
collecting tubules of the renal system, high endothelial 
venules of the lymph nodes, cortical thymocytes of the 
thymus, the epithelium of the bronchi and bronchioles of 
the lung, and type 2 pneumocytes [41].
Here we report the effects of Etx on an endothelial cell 
line, mouse lung endothelial 1G11 cells [42]. The pro-
posed cytotoxic mechanism of action is similar to that 
observed in MDCK cells and follows the defined steps of 
binding, oligomerization, and pore formation in the cell 
membrane.
Materials and methods
Cloning, expression, and purification of pEtx, GFP‑pEtx 
and GFP‑pEtxH106P
pEtx wild type was produced as a fusion protein with 
(GFP-pEtx) or without GFP (pEtx), starting at amino 
acid A47 as described previously [11, 43] and lacking the 
N-terminal but not the C-terminal peptide, which was 
removed by trypsin digestion to produce active toxin 
when required.
Wild type DNA was cloned into the pGEX-4T-1 vec-
tor (GE Healthcare Life Sciences, Marlborough, MA, 
USA) containing the enhanced green fluorescent protein 
(EGFP) coding sequence to produce the corresponding 
recombinant fusion protein as previously described [11]. 
GFP-EtxH106P was generated as described previously 
[22], using the QuikChange multi-site-directed mutagen-
esis kit (Stratagene, San Diego, California, USA). Briefly, 
protein expression was induced overnight in the presence 
of 1 mM isopropyl beta-D-thiogalactopyranoside (IPTG) 
at room temperature (RT), in 250  mL of Luria-Bertani 
(LB) medium containing 50  µg/mL of ampicillin. Cells 
were pelleted and resuspended in 20 mM ice cold phos-
phate buffer (PB) pH 7.5 with 250 mM NaCl, sonicated, 
and centrifuged at 12 000 × g for 20  min at 4  °C. The 
resultant supernatant was incubated with Glutathione 
 SepharoseTM 4B beads (GE Healthcare Life Sciences) for 
1 h at 4 °C. Finally, the recombinant protein was eluted by 
thrombin cleavage in PB containing 2.5 mM  CaCl2.
Activation of epsilon toxin by trypsin
Purified pEtx, GFP-pEtx and GFP-pEtxH106P were acti-
vated with trypsin to form activated Etx, GFP-Etx and 
GFP-EtxH106P [20]. Preparations containing pEtx, GFP-
pEtx or GFP-pEtxH106P were incubated with trypsin-
agarose beads (Sigma-Aldrich, St. Louis, MO, USA) at 
RT for 60  min, and then the trypsin-coated beads were 
removed by centrifugation. Protein concentration was 
determined by Bradford’s method [44] using bovine 
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serum albumin (BSA) as standard. Conversion efficiency 
to Etx, GFP-EtxH106P and GFP-Etx was analyzed with 
SDS-PAGE and Coomassie blue staining.
Immunohistochemical analysis of mouse samples
Male C57BL/6 J mice weighing approximately 20 g were 
housed in standard conditions in temperature-con-
trolled, pathogen-free rooms with free access to standard 
pelleted food and tap water. The experiments were car-
ried out in the animal research facility of the University 
of Barcelona (Bellvitge Campus) in animal preparation 
rooms equipped with the apparatus necessary for isoflu-
rane anesthesia.
Mice were i.v. injected with GFP-Etx or GFP-EtxH106P 
at a final concentration of 2.5 μg/g with phosphate buff-
ered saline (PBS)-1% BSA in a final volume of 50 µL, and 
control mice were only injected with PBS-1% BSA. Prior 
to the i.v. injections, the mice were anesthetized with iso-
flurane and the anesthesia was maintained with the same 
anesthetic until the end of the experiment.
All the animals injected with GFP-Etx died between 5 
and 10 min after injection. No lethal effect was observed 
with either GFP-EtxH106P or control, and mice were 
sacrificed by cervical dislocation 10  min after injection. 
The mice were routinely processed for histopathologi-
cal analysis, and each experimental procedure was per-
formed three times in duplicate.
In order to perform immunohistochemical analysis of 
control, non-injected mice, the animals were anesthe-
tized with intraperitoneal administration of ketamine 
(100 mg/kg) and xylazine (10 mg/kg) and then perfused 
by a gravity-fed system with 4% paraformaldehyde (PFA) 
via the vascular system for 20 min.
Lung sections from injected mice were mounted on 
 SuperFrost® Plus Microscope Slides (#631-0108, Super-
Frost, VWR, Leuven, Belgium), and antigen retrieval 
was accomplished by subjecting deparaffinized sections 
to pressure-cooker unmasking (2100 Antigen retriever, 
BioVendor, Kassel, Germany) in 10 mM Tris and 0.5 mM 
EDTA at pH 9.0. Endogenous peroxidase activity was 
blocked with 10% methanol (v/v) and 2%  H2O2 (v/v) 
in PBS for 30  min. The slides were pre-incubated for 
1  h at RT with PBS containing 20% normal goat serum 
(NGS; Gibco, Paisley, UK), 0.2% Triton, and 0.2% gelatin 
(Merck, Darmstadt, Germany). Then, the sections were 
incubated overnight at 4  °C with the mouse monoclo-
nal anti-MAL E1 antibody (sc-390687, Santa Cruz Bio-
technology, Dallas, Texas, USA) or the rabbit polyclonal 
anti-pEtx [9] at 1:100 diluted in PBS containing 1% NGS, 
0.2% gelatin, and 0.2% Triton. Samples were washed and 
incubated with the appropriate anti-mouse or anti-rabbit 
EnVision+ system- horseradish peroxidase (HRP) labeled 
polymer, and sections were developed by peroxidase 
reaction as explained in [45]. As a control, sections 
were treated identically but omitting the incubation 
with the primary antibody. Nuclei were counterstained 
with hematoxylin, and slides were then dehydrated and 
mounted with dibutylphthalate polystyrene xylene (DPX) 
mounting medium. Slides were examined in a Leica 
DMD108 digital micro-imaging system (Leica, Wetzlar, 
Germany).
Cell lines
The MDCK cell line was purchased from (ATCC ® CCL-
34TM, Manassas, Virginia, USA), the HeLa cell line was 
purchased from (ATCC ® CCL-2TM), the NIH/3T3 cell 
line was kindly provided by the laboratory of Dr Ricardo 
Pérez Tomás (Dept. Pathology and Experimental Thera-
peutics, Faculty of Medicine, Campus Bellvitge, Univer-
sity of Barcelona, Spain) and the murine lung endothelial 
1G11 cell line was originally obtained by Dr Alberto 
Mantovani and Dr Annunciata Vecchi (Instituto Ricerche 
Farmacologiche Mario Negri, Milan, Italy).
MDCK and HeLa cells were maintained in Dulbec-
co’s modified essential  medium (DMEM)-F12 medium 
(31330-038, Gibco) supplemented with 10% fetal bovine 
serum (FBS; Gibco\Invitrogen, Grand Island, NY, 
USA), and 50 U/mL penicillin/streptomycin (P0781, 
Sigma-Aldrich).
NIH/3T3 cells were maintained in DMEM medium 
(D6429, Sigma-Aldrich) supplemented with 10% FBS and 
50 U/mL penicillin/streptomycin.
The 1G11 cells were maintained in DMEM-F12 
medium supplemented with 20% FBS, 50 U/mL penicil-
lin/streptomycin, 150 μg/mL endothelial cell growth sup-
plement (356006, Corning, NY, USA), 100 μg/mL heparin 
(H3149, Sigma-Aldrich), 1% non-essential amino acids 
(M7145, Sigma-Aldrich), and 2  mM sodium pyruvate 
(11360-070, Gibco).
Cells were all grown at 37  °C in a humidified atmos-
phere of 5%  CO2.
In all experiments, MDCK, HeLa and 1G11 cells were 
grown to confluence, but NIH/3T3 cells were grown 
up to 70% confluence according to the manufacturer’s 
instructions.
Confocal microscopy
The cells were grown on coverslips and incubated for 
30  min with 300  nM GFP-pEtx or GFP as a negative 
control, using the same conditions and culture medium. 
After three washes with PBS, the cells were fixed with 
4% paraformaldehyde (PFA) for 12  min at RT. After 
another 3 washes with PBS, the samples were stained 
with TO-PRO-3 (1:1000 dilution, Molecular Probes, Inv-
itrogen, Eugene, Oregon, USA) for 7 min, washed again, 
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and mounted with the Fluoromount aqueous mounting 
medium (F4680, Sigma-Aldrich).
To study and compare the distribution of the corti-
cal actin from Etx and pEtx treated cells, a time-course 
experiment at 15, 30, 60 and 120  min was performed 
incubating MDCK, NIH/3T3 and 1G11 cells with 50 nM 
Etx or pEtx. Next, the cells were fixed with 4% PFA for 
12  min RT and washed thrice with PBS prior to incu-
bation with CytoPainter Phalloidin-iFluor 555 reagent 
(ab176756, Abcam, Cambridge, UK) for 1  h at RT in 
order to stain the actin filaments (F-actin). The cells were 
washed thrice with PBS, the nuclei were stained with 
TO-PRO-3 and the cells were washed and mounted as 
explained above.
Coverslips were examined in a Leica TCS-SL spectral 
confocal microscope (CCiTUB, Bellvitge Campus, Biol-
ogy Unit).
The viability of 1G11 and MDCK cells was recorded in 
a live imaging time-course experiment, exposing the cells 
to 50  nM of Etx, or pEtx as a negative control, during 
120  min at 37  °C. Propidium iodide (PI, P4170, Sigma-
Aldrich) was used in order to detect dead cells. Briefly, 
cells were grown in a chambered polymer coverslip for 
cell culture (80826, µ-Slide 8 well, ibidi, Gräfelfing, Ger-
many) at a final volume of 300 µL/well. PI (red-fluores-
cent nuclear counterstain of dead cells) was added at 5 
µL/mL and was incubated for 5  min in each condition 
previously to Etx or pEtx exposure. Photographs were 
taken every 77 s during 120 min in each condition, and 
a movie was generated overlapping all sections in each 
condition under a Zeiss LSM 880 Confocal Laser Scan-
ning Microscope (CCiTUB, Bellvitge Campus, Biology 
Unit). Fluorescence images were processed with the ZEN 
2.3 SP1 software (Zeiss).
Cytotoxicity assay
MDCK, NIH/3T3 and 1G11 cells were grown in a 96-well 
plate, and the cytotoxic activity of wild type Etx was 
determined using the MTS Assay Kit (G3581, Promega, 
Madison, Wisconsin, USA). Briefly, the assay determines 
the capacity of living cells to reduce yellow tetrazolium 
MTS compound by viable cells to generate a colored 
formazan dye that is soluble in cell culture media. The 
formazan dye is quantified by measuring the absorbance 
at 490 nm.
The cells were exposed to increasing concentrations of 
GFP-Etx (0, 0.5, 1, 5, 10 and 50 nM) for 120 min at 37 °C. 
As a control, the cells were exposed to GFP-pEtx under 
the same conditions. Quadruplicates of each condition 
were performed.
The  CT50 and  LT50 for GFP-Etx were also determined. 
 CT50 defines the concentration of Etx required to kill 50% 
of cells [19, 46], while  LT50 (the median lethal time until 
death) is the mean time to kill 50% of cells [47].
LT50 was determined by exposing cells to 50  nM of 
GFP-Etx at different times (0, 15, 30, 60, 120, 180, and 
240 min) at 37 °C. As a control, the cells were exposed to 
GFP-pEtx or GFP under the same conditions. Each con-
dition was performed in quadruplicate.
Luciferin‑luciferase detection assay
The cells were plated onto a 96-well black polystyrene 
microplate (Merck) with a clear flat bottom and grown 
in 100 µL medium. Then, adenosine triphosphate (ATP) 
release from cells after GFP-Etx or GFP-pEtx exposure 
was measured using the luciferin-luciferase method. 
Luciferase extract lantern from Photinus pyralis (Sigma-
Aldrich) was resuspended at 0.1  µg/µL and desalted in 
a 10  mL 10 DG column (Bio-Rad, Hercules, California, 
USA). d-Luciferin (Sigma-Aldrich) was diluted to a con-
centration of 0.7  µg/µL in ultrapure water and adjusted 
with NaOH to a final pH of 7.4. Then, a mixture of 5 µL of 
d-luciferin and 5 µL of luciferase was added to each cell 
well. The light emitted when ATP reacted with luciferin 
and luciferase was recorded using a FLUOstar OPTIMA 
Microplate Reader (BMG, Ortenberg, Germany) at the 
CCiTUB, Bellvitge Campus Biology Unit, University of 
Barcelona. Once the basal recording signal was stable, 
GFP-pEtx or GFP-Etx was added to each well to obtain 
the desired final concentration of 50 nM. When the bio-
luminescence peak returned to basal level, Triton X100 
(final concentration of 0.2%) was added to evaluate the 
ATP content still present in the cells. Each condition was 
run in triplicate in three independent experiments.
Oligomer complex formation
To analyze the formation of GFP-Etx protein complexes 
in MDCK and 1G11 cells, the cells were grown in 10-cm 
diameter plates and incubated with GFP-Etx for 15, 30, 
60, and 120 min at 37 °C or with GFP-pEtx at 50 nM for 
120 min in the same conditions. As a control, a plate was 
incubated only with cell medium for each cell type.
After incubation, the cells were washed once with PBS 
and then scraped off with 100 µL of ice cold RIPA buffer 
(25  mM Tris–HCl pH 7.4, 150  mM NaCl, 1% NP40, 
0.1% SDS, 1% sodium deoxycholate) supplemented 
with 1:100 protease inhibitor cocktail (#P8340, Sigma-
Aldrich). Harvested cells were lysed by passage through 
a 29-gauge needle (29G) and then sonicated on ice using 
an UP50H ultrasonic processor (Hielscher, Ultrasound 
Technology, Teltow, Germany) at 80% amplitude for 
ten cycles of 0.5  s each. Total cell lysates were quanti-
fied using the  PierceTM BCA Protein Assay kit (Thermo 
Scientific, Massachusetts, USA), and 40 µg of each sam-
ple was electrophoresed in a precast polyacrylamide gel 
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Mini-PROTEAN®  TGXTM (#456-9033, Bio-Rad). Some 
wells were loaded with 0.5  ng of GFP-pEtx, GFP-Etx, 
or GFP recombinant protein as reference band. Later, a 
control assay was performed to compare the oligomer 
formation between MDCK and 1G11 and the non-sen-
sitive NIH/3T3 cells. To do this, the cells were treated 
with 50 nM GFP-pEtx or GFP-Etx for 120 min at 37  °C 
and were lysed and quantified as explained above, and 
the samples were electrophoresed in a 10% polyacryla-
mide SDS-PAGE. Both the precast polyacrylamide gel 
and the 10% polyacrylamide SDS-PAGE were transferred 
to a nitrocellulose membrane Trans-Blot® Turbo TM 
(#1704158, Bio-Rad) and analyzed by Western blot using 
anti-GFP rabbit polyclonal antibody (1:1000 dilution, 
[48]) followed by polyclonal swine anti-rabbit immuno-
globulins/HRP (1:5000 dilution, #P0217, Dako, Glostrup, 
Denmark). To obtain the loading control signal, mem-
branes were developed with anti-α-tubulin clone DM 
1A (1:2000 dilution, #T9026, Sigma-Aldrich) followed by 
rabbit anti-mouse immunoglobulins/HRP (1:5000 dilu-
tion, #P0161, Dako). Membranes were developed with 
 LuminataTMCrescendo western HRP substrate (Milli-
pore, Massachusetts, USA), and the signal was detected 
using an Amersham Imager 600 (GE Healthcare Life 
Sciences).
RNA isolation and semi‑quantitative polymerase chain 
reaction (PCR)
Total RNA was extracted from kidneys and brain mouse 
samples using the RNeasy Lipid Tissue Mini Kit (#74804; 
Qiagen, Hilden, Germany), and the RNeasy Plus Mini Kit 
(#74134; Qiagen) was used in NIH/3T3 and 1G11 cells.
2.5  µg of RNA in each case was used for cDNA syn-
thesis with the First Strand cDNA Synthesis kit (#K1612; 
Fermentas, Massachusetts, USA). Primers for mouse Mal 
detection were designed as:
Mal-Forward: 5′-GCG AAG CTT ATG GCT CCG GCA 
GCG GCT TCG-3′; and Mal-Reverse: 5′-GCG CTC GAG 
ATG AAG ACT TCC ATC TGA TTA-3′, containing HindIII 
and XhoI restriction sites (underlined), respectively.
PCR was developed as follows: 2 min at 95 °C followed 
by 40 cycles of 20  s at 95  °C, 10  s at 62  °C and 10  s at 
70  °C. The product was analyzed in 2% agarose gel and 
RedSafe (21141, iNtRON Biotechnology, Burlington, 
USA) was used to visualize the DNA.
Statistics
Cytotoxicity assay statistics were determined by non-
linear regression analysis using a two-way ANOVA 
with Tukey’s multiple comparison test.  CT50 values for 
cytotoxicity tests were determined from MTS assay 
absorbance values using a nonlinear regression model 
(curvefit) based on the sigmoidal dose–response curve, 
log (inhibitor) vs. normalized response.  CT50 was calcu-
lated with a 95% confidence interval (95% CI) indicated 
as 95% CI (lower–upper).  LT50 values for the cytotoxicity 
test at 50 nM GFP-Etx were determined from MTS assay 
absorbance values over time, and a nonlinear regres-
sion (one-phase exponential decay) was performed and 
revealed a binding at time 0 (Y0 = 94.99%) and a nonspe-
cific plateau (NS = 36.99%) considered as non-sensitive 
cells or background. In order to calculate the real  LT50 
another one-phase exponential decay was performed, but 
the Y0 and the NS were constricted to 94.99 and 36.99, 
respectively.
ATP released in Luciferin–Luciferase assay was calcu-
lated as the area under curve and statistics were deter-
mined by nonlinear regression analysis using a two-way 
ANOVA, followed by Sidak’s multiple comparisons test.
All statistics were calculated using GraphPad Prism 
version 7.00 for Windows (GraphPad Software, La Jolla, 
California, USA).
Results
Etx binds to the plasma membrane of 1G11 cells
To study the effects of Etx on vascular endothelial cells, 
especially those related to the histopathological changes 
described in lung parenchyma of sheep and goats [49] 
and mice injected with GFP-Etx, we used the 1G11 cell 
line, a mouse lung capillary endothelial cell line. First, 
to determine Etx binding to 1G11 cells, we incubated 
the cells with the non-toxic form GFP-pEtx, which has a 
similar binding capacity as the toxic form [20], and the 
cells were analyzed by confocal microscopy. The images 
obtained revealed peripheral staining of GFP-pEtx in 
1G11 cells (green, Figure  1G and arrows in I. See also 
the green mark in Additional file  1A and arrows in C) 
that were very similar to MDCK cells (green, Figure 1A 
and arrows in C), suggesting binding of the toxin to the 
plasma membrane. No GFP-pEtx binding was detected in 
the non-sensitive Etx HeLa cell line (Figures 1D–F) used 
as a negative control. Neither was binding detected in 
1G11 cells incubated with GFP alone (see Additional files 
1D–F), indicating that the binding detected was medi-
ated by Etx and not by GFP.
Etx is cytotoxic in 1G11 cells
MTS cytotoxic assays were performed by incubating 
the cells with GFP-Etx for 120  min at different concen-
trations. The results revealed that MDCK cells were 
around four times more sensitive to GFP-Etx with a  CT50 
0.58 nM (95% CI 0.48 to 0.69) than the 1G11 cells with a 
 CT50 2.17 nM (95% CI 1.05 to 4.58). No cytotoxic effect 
was detected for GFP-pEtx when incubated in 1G11 or in 
MDCK cells (Figure 2A).
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To calculate the  LT50 for GFP-Etx in the 1G11 cell line, 
the cells were exposed to 50  nM of GFP-Etx from 0 to 
240 min, revealing a  LT50 of 50.84 min (95% CI 31.67 to 
78.35 min) (Figure 2B).
Etx produces morphological changes and death of 1G11 
cells
To visualize the effects of Etx on 1G11 cells by micro-
scopic analyses, the cortical actin of cells treated with 
Etx at different periods of time was stained with phal-
loidin-Alexa 555. Etx produced disorganization of the 
cortical actin to a more cytosolic location, producing 
a consequent change in cell morphology (arrows, Fig-
ure  3F). This effect was not observed when cells were 
incubated for the same period (120 min) with GFP-pEtx 
of GFP alone (Figures 3E and D, respectively).
Similar results were observed in the highly sensitive 
MDCK cells (arrowheads, Figure  3C), and no changes 
were detected in cells treated with GFP-pEtx or GFP 
alone (Figures  3B, A, respectively). No changes were 
observed in the cortical actin or in the cell morphology of 
NIH/3T3 cells at 120 min of Etx exposure or with GFP-
pEtx or GFP (Figure 3, panels I, H and G, respectively).
To record cell death produced by Etx, live imaging in 
a time course assay was performed. Although death and 
morphological changes were detected in both MDCK 
and 1G11 cells, the effects on MDCK were faster than in 
1G11 cells (see Additional files 2 and 3, respectively). No 
dead cells were detected with pEtx treatment in MDCK 
or 1G11 cells (see Additional files 4 and 5, respectively). 
Figure  4 shows selected images when the effects of Etx 
were evident and compared to pEtx exposition at the 
same interval time in each condition. No cell death or 
morphological changes were visualized in cells treated 
with pEtx compared to Etx (Figure 4).
Etx induces ATP depletion in 1G11 cells
Etx is a PFT that binds and oligomerizes in the plasma 
membrane of the host cell [30, 50]. The pore-forming 
capacity of Etx can be quantified by ATP release from 
cytosol or internal cell stores [36, 40]. To quantify the 
amount of ATP released, luciferin-luciferase assays were 
performed in 1G11 cells and were compared to MDCK 
(positive control) and NIH-3T3 cells (negative control). 
1G11 cells revealed ATP release after GFP-Etx exposure 
(red line, Figure 5A), although the maximum peak value, 
around 2000 luminescence A.U, was about 15 times lower 
compared to the MDCK cells value which was around 
Figure 1 Etx binds to the plasma membrane of 1G11 mouse 
endothelial cells. Confocal microscopy images show the binding of 
GFP‑Etx to the plasma membrane of MDCK cells, as a positive control 
(A–C) but not to HeLa cells, as a negative control (D–F). GFP‑Etx also 
bound to the plasma membrane of the 1G11 cells (G–I), quite like 
MDCK cells. The cells were incubated with GFP‑pEtx, and nuclei were 
stained with TO‑PRO3 (Blue). Note GFP‑pEtx binding to the plasma 
membrane of MDCK cells (arrows, C) and 1G11 cells (arrows, I). Scale 
bar 20 µm.
Figure 2 Cytotoxic effect of GFP‑Etx in 1G11 mouse endothelial 
cells. 1G11 cells were exposed to increasing concentrations of 
GFP‑Etx for 120 min at 37 °C, and the survival percentage was 
determined by the MTS assay (A). Around 70% of 1G11 dead cells 
were detected starting at 10 nM of GFP‑Etx exposure compared to 
about 0% of dead cells detected with the non‑toxic form of GFP‑pEtx. 
The  CT50 value for 1G11 cells was 2.17 nM (95% CI 1.05 to 4.58) and 
was 0.58 nM for MDCK cells (95% CI 0.48 to 0.69). Treatment with 
50 nM of GFP‑Etx on 1G11 cells for 240 min (B) revealed a  LT50 of 
50.84 min (95% CI 31.67 to 78.35) (*P = 0.02, ****P < 0.00001).
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28 000 luminescence A.U. (red line, Figure 5B). No ATP 
release was detected in the non-sensitive NIH/3T3 cell 
line treated with GFP-Etx (red line, Figure  5C) or in 
all the cell lines treated with GFP-pEtx (black line, Fig-
ures  5A–C). At the end of the experiment, all the ATP 
was virtually released by GFP-Etx in MDCK cells and no 
residual ATP could be measured after cell permeabiliza-
tion with Triton X-100 (red line in the insert, Figure 5B). 
In 1G11 cells, almost all the ATP was released by GFP-
Etx, and very little residual ATP was measured after cell 
permeabilization (red line in the insert, Figure 5A). How-
ever, all the ATP content was detected in NIH/3T3 cells 
after cell permeabilization (red line in the insert, Fig-
ure 5C). The area under curve revealed around 90% and 
60% of ATP released from total ATP content in MDCK 
and 1G11 cells, respectively (Figure 5D).
GFP‑Etx oligomerizes in 1G11 cells
To visualize Etx oligomer complex formation, 1G11 cells 
were incubated with 50  nM GFP-Etx for 15, 30, 60 and 
120 min, and the results were compared to MDCK cells 
under the same conditions. As a negative control, cells 
were incubated, under the same conditions, with GFP-
pEtx for 120 min (which does not form oligomers) or in 
the absence of the toxin. Western blot assays revealed 
similar oligomer complex formation (> 250  kDa) in 
MDCK cells (arrow, lanes 3 to 6, Figure 6A) as in 1G11 
cells (arrow, lanes 3 to 6, Figure  6B). The monomeric 
form of GFP-pEtx, around 60 kDa, was detected in both 
MDCK and 1G11 cells incubated with GFP-pEtx (black 
arrowhead, lane 2, Figures 6A, B, respectively), confirm-
ing that GFP-pEtx binds to cells as a monomer but is 
ineffective in oligomer complex formation. No oligomer 
complex formation was detected in NIH/3T3 cells even 
at 120  min of incubation with GFP-Etx (see Additional 
file 6).
Expression of MAL protein in endothelial cells from mouse 
lung
To investigate the hypothesis of the MAL protein act-
ing as a putative receptor for Etx [33], we first evaluated 
the expression of Mal RNA in 1G11 cells by performing 
Figure 3 Etx produces morphological changes in 1G11 mouse 
endothelial cells. MDCK (A–C), 1G11 (D–F) and NIH/3T3 cells (G–I) 
were treated with 50 nM GFP (A, D and G), GFP‑pEtx (B, E and H) or 
GFP‑Etx (C, F and I) for 120 min at 37 °C. In MDCK and 1G11 cells, 
cortical actin was disorganized, changing its location from the 
plasma membrane to the cytosol (arrowheads in C and arrows in 
F, respectively). Note 1G11 cells with a more rounded morphology 
in GFP‑Etx (F) compared to the elongated morphology in GFP or 
GFP‑pEtx treatments (D and E, respectively). No changes were 
detected in NIH/3T3 cells. Bar 30 µm.
Figure 4 Etx produces the death of 1G11 mouse endothelial 
cells. MDCK cells (A–F) and 1G11 cells (G–L) were treated with pEtx 
(A–C and G–I) or Etx (D–F and J–L) for 120 min at 37 °C. Prior to pEtx 
or Etx treatment, the cells were incubated with propidium iodide 
(PI). Pictures correspond to 40 min of pEtx or Etx action in MDCK 
cells, and 90 min in 1G11 cells. Differential interference contrast (DIC) 
pictures were taken to see the change in cell morphology (A, D, G 
and J). Note a rounded morphology after Etx exposure compared 
to the elongated morphology in pEtx treatment in both MDCK and 
1G11, and PI staining was also detected (red, E and K, respectively). 
Bar 25 µm.
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a RT-PCR assay. We found a single DNA electropho-
retic band of around 500 bp in 1G11 cells and in brain 
and kidneys tissue as a positive control. No band was 
detected in NIH/3T3 cells used as a negative control 
(Figure 7).
The presence of the MAL protein and Etx in lung 
endothelial cells was detected by immunohistochem-
istry assays on lung sections from GFP-Etx- and PBS-
injected mice incubated with α-MAL or α-Etx. While 
the MAL protein was present in the endothelium of 
some vessels in both, PBS- and GFP-Etx-injected mice 
(arrowheads, Figures  8A, C, respectively), Etx was 
only detected in the endothelium of GFP-Etx-injected 
mice (arrowheads, Figure  8D) but not in that of the 
PBS-injected mice (arrowheads, Figure  8B). Moreo-
ver, in control sections in which the primary antibody 
was omitted, no label was observed in the endothelium 
(arrowheads, Additional file 7).
In some samples, blood cells were labeled as a back-
ground (asterisks, Figure 8). In attempts to improve the 
background, a non-injected mouse was perfused with 
4% PFA, and lung sections were fixed and processed. The 
MAL protein was detected in the endothelium of some 
vessels (arrows, Additional file  8D) but was not present 
in the endothelium of control samples (arrows, Addi-
tional file 8B) in which the primary antibody was omit-
ted. Moreover, although there may be variations between 
species, the MAL protein has been detected in type 2 
Figure 5 Etx induces ATP release in 1G11 mouse endothelial cells. ATP release was detected by GFP‑Etx action in 1G11 cells (A) and in MDCK 
cells (B) but not in NIH/3T3 cells (C). The  % of ATP released with respect to the total ATP content was compared between GFP‑Etx treated cells (gray 
columns, D) and GFP‑pEtx treated cells (white columns, D). In A, B and C, cells were incubated with GFP‑Etx (red line) or GFP‑pEtx (black line) for 
120 min. The cells were treated with Triton X‑100 for the last 15 min to quantify total ATP content (inserts, A, B and C). GFP‑Etx induced the release 
of 90% of the ATP content in MDCK cells; 60% in 1G11 cells and no ATP release was detected in NIH/3T3 cells, used as a negative control (D). Each 
condition was run in quadruplicate and in four independent experiments (****P < 0.00001), (n.s non‑significant). Arrowhead marks the beginning of 
incubation with the GFP‑Etx or GFP‑pEtx.
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pneumocytes and in the bronchial epithelial cells [41], 
according to our results (arrowheads, Additional file 8D) 
and (asterisks, Additional file 8C), respectively.
Discussion
In the present study, we used the 1G11 mouse endothe-
lial cell line to further study the effect of Etx on endothe-
lial cells. The results obtained, are relevant as this toxin 
produces edema in certain organs, including lungs and 
brain, as a major histological lesion [28]. The incuba-
tion of 1G11 cells with GFP-Etx revealed its binding to 
the plasma membrane followed by disorganization of the 
cortical actin, with a change in cell morphology showing 
the actin location to be more cytosolic instead of being 
distributed under the plasma membrane. These results 
were supported by Etx-induced cytotoxicity and cell 
death detected by either confocal microscopy, with an 
increase of PI staining of dead cells, or by MTS assay.
Etx effects in MDCK cells appeared faster than in 1G11 
cells, possibly related to a difference in sensitivity to Etx 
in these different cell types. MTS assays revealed a  CT50 
of 2.17 nM, being around 4 times less sensitive for 1G11 
cells compared to the  CT50 of 0.58  nM in MDCK cells, 
and this value is similar to that of previous studies [36]. 
Moreover, the median lethal time  (LT50) in 1G11 cells 
was 50.84  min, which is the optimal incubation time to 
detect 50% of cell death. Although 60  min of exposure 
in 1G11 cells was sufficient to produce statistical differ-
ences with respect to GFP-pEtx or GFP alone, we decided 
to perform viability assays for 120  min at 37  °C which 
would correspond around 2.5 times the  LT50 for GFP-Etx 
in 1G11 cells. The difference between MDCK and 1G11 
cells in GFP-Etx action may be due to the presence of dif-
ferent amounts of the Etx receptor among cell types or 
different efficacy in Etx oligomerization and pore forma-
tion. In support of this hypothesis, Western blot analysis 
revealed oligomer complex formation (> 250 kDa) both in 
MDCK and 1G11 cells exposed to GFP-Etx, although a 
thinner band was detected in 1G11 compared to MDCK 
cells, while no band was observed in MDCK and 1G11 
Figure 6 Etx oligomerizes on 1G11 mouse endothelial cells. 
MDCK (A) and 1G11 (B) cells were treated with 50 nM of GFP‑pEtx or 
GFP‑Etx for different incubation times (lane 1: non‑treated cells; lane 
2: cells treated with GFP‑pEtx for 120 min exposure at 37 °C; lanes 3 
to 6: cells treated with GFP‑Etx for 15, 30, 60, and 120 min exposure 
at 37 °C, respectively; lane 7: GFP‑pEtx recombinant protein; lane 8: 
GFP‑Etx recombinant protein; and lane 9: GFP recombinant protein). 
Note the oligomer complex formation above 250 kDa (arrows, A 
and B) in both MDCK and 1G11 cells. See the GFP‑pEtx around 
60 kDa (black arrowhead, A and B), the GFP‑Etx around 56 kDa (gray 
arrowhead, A and B), and the GFP around 27 kDa (asterisk, A and B). 
α‑tubulin was used as a loading control.
Figure 7 The 1G11 mouse endothelial cell line expresses Mal 
RNA. Reverse transcription‑PCR detection of endogenous mouse 
Mal mRNA was extracted from kidneys and brain from mouse tissue 
(as a positive control) and from NIH/3T3 cells (as a negative control) 
and was compared to 1G11 cells. Samples were electrophoresed 
in 2% agarose gel. A band corresponding to Mal RNA weight was 
detected at around 500 bp in 1G11 cells and in brain and kidneys but 
not in NIH/3T3 cells. The 18S rRNA was used as a control. The DNA 
molecular weight marker is represented on the left (bp).
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cells following GFP-pEtx treatment. These results also 
suggest that the efficacy of oligomer complex formation 
and Etx sensitivity were lower in the 1G11 than in MDCK 
cell line. Consequently, under the same conditions, the 
luciferin-luciferase assay showed a luminescence peak 
value in both MDCK (28 000 A.U.) and 1G11cells (2000 
A.U.) related to ATP release, but it was not detected in 
the non-sensitive NIH/3T3 cell line. In MDCK cells 
the peak value was 14 times higher than in 1G11 cells, 
which could be explained by a different ability to form 
Etx complexes due to a different amount of Etx recep-
tor expression in each cell type or different mitochon-
drial population among cell lines with less ATP content 
in 1G11 cells compared to MDCK cells. Furthermore, the 
sensitivity to Etx is different in each cell type, becoming 
around 30–40% of non-sensitive in 1G11 cells compared 
to the less than 10% in MDCK cells, which may be attrib-
utable to different stages of cell physiology with poor Etx 
receptor expression.
The MAL protein has been implicated in specific Etx 
binding and cytotoxic activity, suggesting that MAL is a 
putative receptor for Etx [33, 34]. Moreover, MDCK cells 
express the MAL protein [32, 39], which is also expressed 
in other cells as MOLT4 or Jurkat [36] and FRT cells 
[40, 51], which are also sensitive to Etx. Here, we show 
Etx activity for the first time in an endothelial cell line in 
which Mal RNA is present, supporting the hypothesis of 
MAL as a key element of Etx action. Although we tested 
various MAL antibodies, none proved suitable to recog-
nize the endogenous MAL protein in 1G11 or MDCK 
cells by confocal microscopy (data not shown). This may 
be due to low endogenous protein expression or failure of 
the antibodies tested to recognize the MAL protein from 
different species in culture cells. However, immunohis-
tochemistry assays of mouse lung sections detected the 
MAL protein in the endothelium after antigen retrieval 
treatment. This label coincides with Etx detection in the 
endothelium of lung sections from GFP-Etx-injected 
mice, supporting the hypothesis of MAL as the putative 
receptor for Etx. MAL protein was also detected in the 
epithelium of bronchioles and in type 2 pneumocytes 
from mouse, coinciding with previous results obtained 
in human [41], although the effect of Etx on these cells 
remains unknown. However, MAL protein was not 
reported in human lung endothelium probably due to 
protein expression variability among species.
In conclusion, Etx binds, oligomerizes and produces 
a cytotoxic effect on the endothelial cell line 1G11 from 
mouse lung in a similar way as the well-characterized 
MDCK cell line. Accordingly, 1G11 cells become a new 
model to study the cellular and molecular mechanisms 
of Etx in the endothelium. These results suggest a cyto-
toxic effect of Etx on lung endothelial cells that would be 
responsible for the histopathological changes observed 
in Etx intoxicated animals. In addition, the MAL protein 
has been postulated to be the putative receptor for Etx; 
in fact, we have demonstrated the presence of Mal RNA 
expression in 1G11 cells, and MAL protein expression in 
the endothelium of some vessels from mouse lung, rein-
forcing the hypothesis of the MAL protein as the Etx 
receptor, or at least, that the presence of the MAL protein 
is crucial for the Etx binding and cytotoxic activity.
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Additional file 1. GFP‑pEtx, but not GFP alone, binds to 1G11 mouse 
endothelial cells. Confocal microscopy images show the binding of 
GFP‑pEtx but not GFP alone, to the plasma membrane of 1G11 cells. The 
cells were incubated with GFP‑pEtx (A–C) or GFP alone (D–F), and the 
nuclei were stained with TO‑PRO3 (Blue, B, C, E and F). Note GFP‑pEtx 
binding to the plasma membrane of 1G11 cells (green, in A and arrows in 
C) which was not detected in incubations with GFP alone (D and F). Scale 
bar 25 µm. 
Additional file 2. Etx produces MDCK cell death. MDCK cells were 
pre‑incubated with propidium iodide (PI) prior to treating the cells with 
Etx for 120 min at 37 °C. Differential interference contrast shows the cell 
Figure 8 Endothelial cells from mice lungs express the MAL 
protein. Immunohistochemistry assays against the MAL protein (A 
and C) or Etx (B and D) on lung sections from mice injected with PBS 
(A, B) or GFP‑Etx (C, D). MAL protein expression in the endothelial 
cells of some vessels was present in both PBS‑ and GFP‑Etx‑injected 
mice (brown, arrowheads in A and C, respectively). Etx was present 
in GFP‑Etx‑injected mice (brown, arrowhead in D) but not in the PBS 
control mice (arrowheads in B). Note unspecific staining from blood 
cells inside vessels in all conditions (brown, asterisk in A–D). Nuclei 
were stained with hematoxylin. Scale bar 25 µm.
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morphology (grey), and PI was used to detect the nuclei of dead cells 
(red). Most of the cells were affected by Etx. Scale bar 20 µm. 
Additional file 3. Etx produces 1G11 mouse endothelial cell death. 
1G11 cells were pre‑incubated with propidium iodide (PI) prior to treating 
the cells with Etx for 120 min at 37 °C. Differential interference contrast 
shows the cell morphology (grey), and PI was used to detect the nuclei of 
dead cells (red). Most of the cells were affected by Etx. Scale bar 20 µm. 
Additional file 4. pEtx does not produce MDCK cell death. MDCK cells 
were pre‑incubated with propidium iodide (PI) prior to treating the cells 
with pEtx for 120 min at 37 °C. Differential interference contrast shows the 
cell morphology (grey), and PI was used to detect the nuclei of dead cells 
(red). No MDCK cells were affected by pEtx. Scale bar 20 µm. 
Additional file 5. pEtx does not produce 1G11 mouse endothelial cell 
death. 1G11 cells were pre‑incubated with propidium iodide (PI) prior to 
treating the cells with pEtx for 120 min at 37 °C. Differential interference 
contrast shows the cell morphology (grey), and PI was used to detect the 
nuclei of dead cells (red). No 1G11 cells were affected by pEtx. Scale bar 
20 µm. 
Additional file 6. Etx does not oligomerize in NIH/3T3 non‑sensitive 
cells. MDCK, 1G11 and NIH/3T3 cells were treated with 50 nM of GFP‑pEtx 
(lane 1, 3 and 5, respectively) or GFP‑Etx (lane 2, 4 and 6, respectively) 
for 120 min at 37 °C. Oligomer complex formation is detected above 
250 kDa (arrow) in both MDCK and 1G11 cells but not in the NIH/3T3 
cells. α‑tubulin was used as a loading control. Note less intensity in 1G11 
complex compared to MDCK cells complex. 
Additional file 7. Secondary‑HRP antibodies did not bind to the 
endothelium from lung sections of injected mice. Immunohistochem‑
istry assays of lung sections from mice injected with PBS (A and B) or 
GFP‑Etx (C and D) were revealed with anti‑mouse EnVision+ system‑HRP 
(A and C) or anti‑rabbit EnVision + system‑HRP (B and D) as a secondary 
antibody. Incubations were developed as explained in the Materials and 
Methods sections but omitting the primary antibody. No binding was 
detected in the endothelium of any condition (arrowheads), with only a 
little background of some blood cells from lungs sections being revealed 
with the secondary antibody (brown, A and C). Nuclei were stained with 
hematoxylin. Scale bar 25 µm. 
Additional file 8. Anti‑MAL staining on mouse lungs. Immunohisto‑
chemistry assays on lung sections from perfused mouse revealed MAL 
protein expression in endothelial cells of some vessels. Lung sections were 
incubated with the MAL antibody (C and D) or by omitting the primary 
antibody (A and B). All the sections were incubated with anti‑mouse EnVi‑
sion+ system‑HRP and developed as explained in the Materials and Meth‑
ods section. Note MAL protein expression in the endothelium (brown, 
arrows in D). However, it was not detected in the control conditions omit‑
ting the incubation with the primary antibody (arrows in B). MAL was also 
expressed in bronchial epithelial cells (brown, asterisk in C) and in type 2 
pneumocytes (brown, arrowhead in D). B and D are magnifications from 
A and C images, respectively. Scale bars correspond to 50 µm in A and C, 
and 20 µm in B and D.
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